CRNX · Crinetics Pharmaceuticals Inc
Price
Snapshot
50 fields · last close| Market Cap | $9.01B |
| P/E | — |
| Float | 103.0M |
| Beta | 0.45 |
| Volatility | 11.2% |
| Exchange | NASDAQ |
| Sector | Pharmaceuticals |
| Cap tier | Mid cap |
| Macro sensitivity | Low |
| Clavix score | 50 |
| Price | 84.95 |
| Change | +0.00% |
| Prev Close | 84.95 |
| Open | 84.96 |
| Day Low | 84.92 |
| Day High | 85.01 |
| Avg Vol | 3 |
| Avg $ Vol | $256.2M |
| 52W High | 85.01 |
| 52W Low | 30.25 |
| 52W Pos | 99.9% |
| From High | −0.07% |
| From Low | +180.83% |
| Max DD 1Y | −42.21% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +0.50% |
| SMA 50 | +13.52% |
| SMA 200 | +68.41% |
| RSI (14) | 89.8 |
| Vol 30D | 2.1% |
| Vol 90D | 122.4% |
| 1Y Range | 30–85 |
| Daily bars | 503 |
| Perf Week | +0.20% |
| Perf Month | +1.71% |
| Perf Quarter | +146.09% |
| Perf Half Y | +108.82% |
| Perf Year | +177.16% |
| Perf YTD | +81.79% |
| Prev Day | +0.00% |
| Clavix | D+ |
| Debt / Eq | 0.00 |
| Curr Ratio | 12.32 |
| Int Cover | — |
| FCF Margin | — |
| Rev Growth | +2336.3% |
| Profit | Unprofitable |
| Leverage | Low |
| Sector rank | 15 / 15 |
Clavix risk grade
regraded every trading dayCRNX grades D+, 50 of 100. Steadiest on News Sentiment (67), most exposed on Price Stability (30, weak). 1 of the 4 weighted dimensions sit above the Pharmaceuticals median. Ranks 15 of 15 in Pharmaceuticals by Clavix score.
How rough the ride is
| CRNX | Pharmaceuticals median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.45 | 0.43 |
| Volatilityannualized | 11.2% | 10.7% |
| Max drawdown, past yearworst peak-to-trough fall | −42.2% | — |
| Typical daily movemedian absolute daily change | 1.41% | — |
| Days beyond ±3%of the last 252 sessions | 5923% | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| CRNX | Pharmaceuticals median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.45 | 0.43 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Low67% of 15 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Pharmaceuticals names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| CRNX | |
|---|---|
| 1 week | +0.2% |
| 1 month | +1.7% |
| Year to date | +81.8% |
| 1 year | +177.2% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| CRNX | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30since 9 Jul |
| Average score0 most bearish, 100 most bullish | 71 |
| Bullish · bearisharticles above 60 · below 40 | 22 · 4 |
| Directionarticles whose tone is improving vs worsening | 22 ↑ 4 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 15 Pharmaceuticals names Clavix covers; the tick is the sector median.
Growth
| CRNX | |
|---|---|
| Revenue growthyear over year | +2336.3% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Pharmaceuticals median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Against Pharmaceuticals
15 companies| Metric | CRNX | Sector spread | Median |
|---|---|---|---|
| Beta | 0.45 | 0.43 | |
| Volatility | 11.2% | 10.7% | |
| Debt / equity | 0.00 | 0.94 | |
| Current ratio | 12.32 | 1.86 |
Recent news
most recent scored articles · the chip is the article’s score · click to openVertex Pharmaceuticals has finished buying Crinetics Pharmaceuticals (CRNX), which develops treatments for hormone-related diseases. Vertex also announced additions to its executive team to support growth. The article body is short and provides few additional details.
Crinetics filed an 8-K updating shareholders on its pending acquisition by Vertex Pharmaceuticals, originally announced July 6, 2026, in which Vertex's subsidiary will merge into Crinetics, making it a wholly-owned Vertex subsidiary. A special shareholder meeting to vote on the merger is set for August 28, 2026. Three purported shareholders filed complaints on August 6 and August 17, 2026, though the article text is cut off before describing them.
An HSR antitrust filing (Transaction Number 20261890) dated August 12-14, 2026 shows Vertex Pharmaceuticals Incorporated as the acquiring party and Crinetics Pharmaceuticals, Inc. as the acquired party, with granting status listed as 'Granted'.
Crinetics Pharmaceuticals filed an 8-K reporting that the HSR Act waiting period for its pending merger with Vertex Pharmaceuticals expired on August 12, 2026, and that required antitrust approvals in Austria, Germany, and Australia have been obtained as of August 13, 2026.
A law firm, Monteverde & Associates, announced it is investigating the mergers of CRNX and three other companies (PSBQ, D, and NEE), though the full details of the announcement were cut off.
Nearest peers by size
Pharmaceuticals| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| AXSM | Axsome Therapeutics Inc | B | $10.91B | — | 0.81 | Compare |
| CORT | Corcept Therapeutics Inc | C- | $12.19B | 216.52 | 0.50 | Compare |
| ELAN | Elanco Animal Health Inc | B- | $12.20B | — | 1.75 | Compare |
| JAZZ | Jazz Pharmaceuticals PLC | A- | $16.07B | 17.04 | 0.38 | Compare |
| MANE | Veradermics Inc | D- | $4.08B | — | -0.14 | Compare |
| VTRS | Viatris Inc | B+ | $20.71B | — | 0.91 | Compare |
| ZTS | Zoetis Inc | B | $31.87B | 12.03 | 0.69 | Compare |
| RPRX | Royalty Pharma PLC | A | $36.73B | 45.07 | 0.38 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.